Lysosomal Therapeutics
Cambridge, US · Founded 2011 · Delaware corporation · 4 known investors
Lysosomal Therapeutics Inc. (LTI) develops small-molecule drug therapies for severe neurological diseases affecting movement and cognition, with a lead candidate, LTI-291, targeting GBA-associated parkinsonism, a form of Parkinson's disease linked to GBA1 gene mutations. The company's drug discovery approach draws on the biological link between common neurodegenerative diseases and rare lysosomal genetic disorders.
Founders & leadership
Lysosomal Therapeutics was founded in 2011 by Dimitri Krainc.
DK
Dimitri KraincFounder
RC
Robert CarpenterExecutive
CB
Cornelis BeenExecutive
Board
SH
Steven HallBoard director
CN
Carole NuechterleinBoard director
BD
Bernard DavitianBoard director
BB
Bruce BoothBoard director
CT
Clay ThorpBoard director
HT
Henri TermeerBoard director
PW
Peter WirthBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$38M disclosed across 4 rounds · 2014–2019
▶$1MraisedNov 2019 · 10 investors · BiotechnologyRule 506(b)
▶$1MraisedNov 2019 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven E. HallDirector
- Carole NuechterleinDirector
- Clay ThorpDirector
- Daniel GeffkenExecutive Officer
- Bruce L. BoothDirector
- Robert CarpenterExecutive Officer, Director
- Cornelis BeenExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $1M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$26.1MraisedJan 2017 · 9 investors · BiotechnologyRule 506(b)
▶$26.1MraisedJan 2017 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven HallDirector
- Bernard DavitianDirector
- Daniel GeffkenExecutive Officer
- Bruce BoothDirector
- Cornelis BeenExecutive Officer, Director
- Robert CarpenterExecutive Officer, Director
- Carole NeuchterleinDirector
- Clay ThorpDirector
- Offering amount
- $26.1M
- Amount sold
- $26.1M
- First sale
- Jan 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6MraisedOct 2016 · 9 investors · BiotechnologyRule 506(b)
▶$6MraisedOct 2016 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven HallDirector
- Carole NuechterleinDirector
- Bernard DavitianDirector
- Robert CarpenterExecutive Officer, Director
- Bruce BoothDirector
- Cornelis BeenExecutive Officer, Director
- Clay ThorpDirector
- Offering amount
- $6M
- Amount sold
- $6M
- Proceeds to insiders
- $250K
- First sale
- Oct 2016
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$4.8MraisedMay 2014 · 11 investors · PharmaceuticalsRule 506(b)
▶$4.8MraisedMay 2014 · 11 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dimitri KraincDirector
- Cornelis BeenExecutive Officer, Director
- Robert CarpenterExecutive Officer, Director
- Henri TermeerDirector
- Peter WirthDirector
- Offering amount
- $4.8M
- Amount sold
- $4.8M
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Lysosomal Therapeutics do?
- Lysosomal Therapeutics Inc. (LTI) develops small-molecule drug therapies for severe neurological diseases affecting movement and cognition, with a lead candidate, LTI-291, targeting GBA-associated parkinsonism, a form of Parkinson's disease linked to GBA1 gene mutations. The company's drug discovery approach draws on the biological link between common neurodegenerative diseases and rare lysosomal genetic disorders.
- Who founded Lysosomal Therapeutics?
- Lysosomal Therapeutics was founded by Dimitri Krainc in 2011.
- Who are Lysosomal Therapeutics's investors?
- Lysosomal Therapeutics's investors include Atlas Venture, Hatteras Venture Partners, Lilly Ventures, Roche Venture Fund.
- How much funding has Lysosomal Therapeutics raised?
- Lysosomal Therapeutics has disclosed $38M raised across 4 rounds.
- Where is Lysosomal Therapeutics headquartered?
- Lysosomal Therapeutics is headquartered in Cambridge, US.